Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CBST

Cubist Pharmaceuticals (CBST) Stock Price, News & Analysis

Cubist Pharmaceuticals logo

About Cubist Pharmaceuticals Stock (NASDAQ:CBST)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Cubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Receive CBST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cubist Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CBST Stock News Headlines

The Man I Turn to In Times Like This
A storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when publisher Brett Aitken turns to Whitney Tilson—a man CNBC once dubbed “The Prophet.” Tilson just released a new prediction that runs counter to what mainstream finance is telling you.
Key facts about Cubism
CBST:CA The Cannabist Company Holdings Inc.
What is Cubism?
Cubist Stock Hits New 52-Week High (CBST)
See More Headlines

CBST Stock Analysis - Frequently Asked Questions

Cubist Pharmaceuticals Inc (NASDAQ:CBST) released its quarterly earnings data on Tuesday, October, 21st. The biopharmaceutical company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.54. The company's revenue for the quarter was up 16.2% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cubist Pharmaceuticals investors own include Intercept Pharmaceuticals (ICPT), Novavax (NVAX), Bausch Health Companies (BHC), Booking (BKNG), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY) and FLEETCOR Technologies (FLT).

Company Calendar

Last Earnings
10/21/2014
Today
5/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBST
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CBST) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners